Oncternal, Tokalas deal

Cancer companies Oncternal and Tokalas merged and will retain the Oncternal name. Oncternal’s cirmtuzumab (UC-961), a humanized IgG1 mAb against receptor tyrosine kinase-like orphan receptor 1 (ROR1), is in Phase I testing to treat relapsed or refractory chronic lymphocytic leukemia (CLL). The companies plan to conduct additional trials this year for cirmtuzumab in breast cancer and mantle cell lymphoma (MCL). ...